Project Grant K99DA060906

Award Date 4/15/25
Completion Date 3/31/26
Dollars Obligated $118K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award in the amount of $715,238 was issued on January 15, 2025 by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The project will conduct a large-scale genetic study involving a survey of 500,000 diverse individuals to investigate the genetic basis of opioid-related traits and opioid use disorder (OUD). The research aims to elucidate genetic risk factors across the stages of opioid use, from initial use...
This $351,097 federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the Mass General Brigham Interdisciplinary Clinical Pain Research Training Program. The program aims to establish a rigorous and supportive interdisciplinary training program in clinical pain research, providing protected research time and dedicated training to a diverse pool of postdoctoral fellows....
This $362,080 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the role of the anterior cingulate cortex (ACC) in regulating spinal cord excitability and associative opioid analgesic tolerance. The primary awardee, Yale University, will use a combination of transgenic tools, fiber photometry, and optogenetics to determine how the ACC integrates context and drug signals to...
This $2,314,276 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at Emory University to develop novel methods for experimentally inducing and measuring nociceptive-specific (pain-specific) responses in humans. The key objectives are to: Identify and utilize naturally occurring skin regions devoid of innocuous warm fibers to selectively stimulate nociceptors and obtain...
This $444,125 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to explore the role of the LRRC55 protein in pain mechanisms. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using knockout mice, 2) quantify changes in LRRC55 expression in pain-sensing neurons after chronic pain, and 3) test whether LRRC55 knockdown in these...
This federal Project Grant award, valued at $238,276, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding supports research at the University of California, Irvine to investigate the role of the enzyme N-acylethanolamine acid amidase (NAAA) in the development of hyperalgesic priming, a model for studying the transition from acute to chronic pain. The project aims to identify the receptor...
This $2,103,564 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of the nuclear receptor NR4A1 in mediating pain resolution and limiting chronic pain. The award to the University of Cincinnati will fund research across three specific aims: Testing whether NR4A1 in macrophages controls the resolution of inflammation and postoperative pain in mice....
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
This Project Grant award for $242,061 from the National Institute of Neurological Disorders and Stroke (NINDS) is part of the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will establish a rigorous interdisciplinary training program in clinical pain research at Mass General Brigham (MGB) in Boston. The program will support 8-12 postdoctoral fellows over 5 years, with the goal of expanding the pool of early career investigators capable of launching successful careers in...
This National Institutes of Health National Institute on Drug Abuse Project Grant award of $234,364.35 supports research from March 1, 2021 through August 31, 2022 at clinical practices of the University of Pennsylvania located in Pennsylvania. The research aims to characterize a nociception-active basolateral amygdala to anterior cingulate cortex circuit that contributes to affective-attention pain behaviors, and determine its overlap with endogenous mu opioid receptor systems. The grant also...

This $118,457 federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to characterize the genetic architecture underlying chronic pain and addiction risk. The principal investigator, Dr. Sylvanus Toikumo, will use genomic analyses, causal inference, and gene mapping techniques to elucidate the genetic underpinnings of chronic pain and identify potential therapeutic targets. The project aims to enhance Dr. Toikumo's skills in pain phenotyping, statistical genetics, computational genomics, and gene mapping, with the ultimate goal of informing the development of novel, non-addictive analgesic medications. The award is part of a K99/R00 Pathway to Independence program, and the research will be conducted at the University of Pennsylvania, Children's Hospital of Philadelphia, and a yet-to-be-determined research institution.

Generated 4/29/25, 3:07 AM